Skip to main content
SpringerLink
Log in

Focus on multiple myeloma at ASH 2015

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Multiple myeloma was prominently featured during the American Society of Hematology 2015 meeting. Important presentations were related to standards of first-line therapy of myeloma, disease assessment, and treatment of relapsed disease. New innovative treatments for myeloma are emerging, which will likely open new therapeutic avenues in the near future. This review aims to give a brief overview of the topic, focusing on presentations with relevance for clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Attal M, Lauwers-Cances V, Hulin C, et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 trial). Blood. 2015;126:391.

    Google Scholar 

  2. Moreau P, Hulin C, Macro M, et al. Bortezomib, thalidomide and dexamethasone (VTD) is superior to bortezomib, cyclophosphamide and dexamethasone (VCD) prior to autologous stem cell transplantation for patients with de novo multiple myeloma. Results of the prospective IFM 2013-04 trial. Blood. 2015;126:393.

    Article  Google Scholar 

  3. Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood. 2016;127(21):2569–74.

    Article  PubMed  Google Scholar 

  4. Durie B, Hoering A, Rajkumar V, et al. Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777. Blood. 2015;126:25.

    Google Scholar 

  5. Moreau P, Attal M, Karlin L, et al. Prospective evaluation of MRI and PET-CT at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial. Blood. 2015;126:395.

    Article  Google Scholar 

  6. Moreau P, Masszi T, Grzasko N, et al. Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (Ird), significantly extends progression-free survival (PFS) for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM): the phase 3 tourmaline-MM1 study (NCT01564537). Blood. 2015;126:727.

    Article  Google Scholar 

  7. Moreau P, Masszi T, Grzasko N, et al. TOURMALINE-MM1 study group. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–34.

    Article  CAS  PubMed  Google Scholar 

  8. Avet-Loiseau H, Fonseca R, Siegel D, et al. Efficacy and safety of carfilzomib, lenalidomide, and dexamethasone vs lenalidomide and dexamethasone in patients with relapsed multiple myeloma based on cytogenetic risk status: subgroup analysis from the phase 3 study aspire (NCT01080391). Blood. 2015;126:731.

    Google Scholar 

  9. Chng WJ, Goldschmidt H, Dimopoulos MA, et al. Efficacy and safety of carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma based on cytogenetic risk status: subgroup analysis from the phase 3 study endeavor (NCT01568866). Blood. 2015;126:30.

    Google Scholar 

  10. San Miguel J, Mateos MV, Shah JJ, et al. Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): keynote-023. Blood. 2015;126:505.

    Google Scholar 

  11. Badros AZ, Kocoglu MH, Ma N, et al. A phase II study of anti PD-1 antibody pembrolizumab, pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2015;126:506.

    Google Scholar 

  12. Plesner T, Arkenau HT, Gimsing P, et al. Daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: updated results of a phase 1/2 study (GEN503). Blood. 2015;126:506.

    Google Scholar 

  13. Abbas AS, Shi V, Wang M, et al. Remissions of multiple myeloma during a first-in-humans clinical trial of T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor. Blood. 2015;126:LBA-1.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Medicine, Center for Oncology and Hematology & Palliative Care, Wilhelminenspital, Montleartstraße 37, 1160, Vienna, Austria

    Niklas Zojer

Authors
  1. Niklas Zojer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Niklas Zojer.

Ethics declarations

Conflict of interest

N. Zojer has received honoraria from Celgene, Janssen-Cilag, Amgen, BMS, Takeda, and Novartis within the last 18 months.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zojer, N. Focus on multiple myeloma at ASH 2015. memo 9, 127–130 (2016). https://doi.org/10.1007/s12254-016-0283-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-016-0283-3

Keywords

Search

Navigation